Alzheimer’s Disease Recovery Program

We’re finally making a difference.

Hidden Peaks Psychology® is now conducting Alzheimer’s Disease research.

This is a noninvasive intervention using 40hz visual and auditory waves to dissolve amyloid plaques. This treatment protocol was developed by the Picower Institute at M.I.T.

For information on the treatment program, peer-reviewed research, and safety protocols please see below:

The Gamma Brain-Wave machine is designed to deliver precisely 40hz gamma waves through the auditory and optic nerve tracks of the brain.

This is a passive intervention that allows the patient to recline while the machine delivers light and sound stimulation to the interior of the brain.

This brain-wave stimulation is called entrainment and it is a proven method at reducing Aβ load (amyloid plaque) and improving brain connectivity

By delivering gamma waves to the auditory and visual cortex of the brain, the 40hz frequency passes through the lobes where the amyloid plaques are held.

This “access” to the brain without surgery or medication is the safest way of treating this debilitating disease.

FAQs

  • Currently, we do not have an established cure for Alzheimer’s disease. The scientific cause of Alzheimer’s is amyloid plaques, and medications nor surgery is useful at ridding the brain of this protein.

    Our innovative treatment is the only effective approach at reducing those amyloid plaques. This treatment is not FDA approved, but an experimental approach within a losing battle.

  • Every patient receives baseline cognitive testing: pre-treatment.

    During every session, patients are observed and the intervention is carried out by a Dr.

    Every patient receives cognitive testing post-treatment to compare immediate progress. Another cognitive assessment is completed at 2 months post-treatment to track long-term positive effects.

  • Patients receive 1 hour of dual audio and visual waves, set at 40hz gamma frequency, per day.

    This is repeated for 7 continuous days, to achieve a total of 7 hours of gamma brain-wave entrainment.

  • We are currently running two clinical trials.

    One is through several nursing homes with IRB approval. These are patients who receive treatment in group format at their living facilities.

    The other is a paid experimental trial. These are patients who apply for treatment and pay out of pocket. They receive treatment at our private practice location. The flat fee for inclusion in the clinical trial is $5,000.

  • The audio and visual waves are intense and uncomfortable at first. It normally takes 1-4 sessions to adjust to the light and sound.

    The treatment does not cause pain and there is minimal to no risk of injury.

  • According to MIT’s most recent publication (Dec ‘22), gamma wave treatment for Alzheimer’s disease “produces no serious adverse effects and is well tolerated”.

    Patient safety and comfort is monitored by a neuropsychologist throughout the entire treatment.

    Collaboration/Communication with every patient’s primary care provider (PCP) is critical in maintaining positive treatment results.

Meet the Team

  • Dr. Ruel Billones (Ed.d & Ph.D)

    Lead Researcher:

    Dr. Billones is a well established researcher with a focus on the cross section between medical disease and mental health. He has extensive experience with grant funded projects that investigate life stressors and their dramatic impact on our physical health.

    Dr. Billones has held important lead research positions while employed at various top notch organizations. Such as the NIH, USF, and Yale University. He is now at Springfield Psychiatric Hospital in Maryland.

  • Dr. Fabian Consbruck (Psy.D.)

    Lead Clinician:

    Dr. Consbruck has been involved in many brain research endeavors while employed at various locations. He collected data while in the U.S. Air Force for TBI. He compared dementia with diabetes while at a memory disorder clinic. And he was the director of psychology at Thrive Behavioral Sciences, the largest geriatric provider in Florida, which published a new Geriatric Rehabilitation Model.